Web15 Sep 2024 · Separately, Seattle Genetics has granted Merck an exclusive license to commercialize TUKYSA (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Seattle Genetics will receive $125 million … Web22 Feb 2024 · According to Seagen – known as Seattle Genetics until a name change last year – Tukysa is the first HER2 tyrosine kinase inhibitor shown to improve overall and progression-free survival (PFS)...
Seattle Genetics and Merck Announce Two Strategic …
Web1 Aug 2015 · Mar 2024 - Present1 year 2 months. Bothell, Washington, United States. Responsible for the design, development, implementation, and sustainability of all learning solutions for commercial non ... Web14 Sep 2024 · Seattle Genetics is also eligible for milestone payments up to $2.6 billion. The second deal is Merck licensing Seattle Genetics’ Tukysa (tucatinib) for HER2-positive cancers in Asia, the Middle East and Latin America, and other areas outside of the U.S., Canada and Europe, where Seattle Genetics will continue to hold the sales rights. spi clean energy
Merck Announces Two Oncology Collaborations with Seattle Genetics
Web20 Apr 2024 · The FDA has approved Seattle Genetics' breast cancer drug Tukysa (tucatinib) four months early, including in certain patients whose disease has spread to the brain. Tukysa has been approved... Web2024年4月18日，美国FDA批准西雅图遗传学公司（Seattle Genetics）开发的选择性HER2抑制剂Tucatinib（ARRY-380, ONT-380）上市，与曲妥珠单抗和卡培他滨联用，用于治疗手术无法切除或转移性经治晚期HER2阳性乳腺癌成人患者。这是今年FDA批准的第4个小分子靶向抗 … Web12 Aug 2024 · Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful … spi cinemas owner